Manila Times Business
Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 SIRIUS COPD Study of SKB378/WIN378
COPD study initiation expands SKB378/WIN378 development into a second major respiratory diseaseSKB378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026SKB378/WIN378 has the potential to be the first-to-market,ultra long-acting anti-TSLP antibody for asthma and COPD, with Phase 3 initiation in asthma planned for Q4 2026CHENGDU, China, June 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Bata, Django, De la Cruz lead coaching staff of new billiards NSA
2h ago
Tokenized Cash Management Advisory Group Publishes the Scope of Its Work Program
2h ago
COSMOBEAUTÉ MALAYSIA & BEAUTYEXPO 2026 RETURNS TO KLCC TO DRIVE B2B EXCELLENCE AND NEW BUSINESS FRONTIERS
2h ago
Regent Hong Kong Named Among First-Ever Winners of Condé Nast Traveler's Triple Crown Award
2h ago